Literature DB >> 21460715

Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management.

Alessandra Vultaggio1, Enrico Maggi, Andrea Matucci.   

Abstract

PURPOSE OF REVIEW: The rapid expansion of the use of biologics has resulted in an increase in adverse drug reactions, some of which can be life-threatening, due to the immunogenicity of these new drugs. This review summarizes the current knowledge of the pathogenic mechanisms of biologics-induced hypersensitivity reactions and highlights the most useful diagnostic and prophylactic tools now available in the clinical management of immunogenicity associated with biologics. RECENT
FINDINGS: Over the last few years, many drug-related or patient-related factors contributing to the immunogenicity of biologics have been identified, thus allowing a better identification of patients at risk of reaction. Recent studies show that different mechanisms sustain hypersensitivity reactions toward biologics, and the application of novel methods for detecting antidrug antibodies has allowed the involvement of specific IgE isotypes. Additionally, experience with procedures of desensitization to biologics continues to grow.
SUMMARY: Considering the increased use of the biological therapies in different clinical conditions, the definition of diagnostic and prophylactic strategies represents an unavoidable necessity in the management of potentially reactive patients in order to improve the safety profile of biologics.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21460715     DOI: 10.1097/ACI.0b013e3283464bcd

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  18 in total

1.  A study investigating the association of dermatological and infusion reactions to infliximab and infliximab trough levels.

Authors:  Vivian Huang; Neil Dhami; Darryl Fedorak; Connie Prosser; Carol Shalapay; Karen I Kroeker; Brendan P Halloran; Levinus A Dieleman; Richard N Fedorak
Journal:  Can J Gastroenterol Hepatol       Date:  2015 Jan-Feb

2.  Desensitization to rituximab in a multidisciplinary setting.

Authors:  Patrícia Amorós-Reboredo; Jaime Sánchez-López; Carla Bastida-Fernández; Fernando do Pazo-Oubiña; Núria Borràs-Maixenchs; Eva Giné; Antonio Valero; Natàlia Creus-Baró
Journal:  Int J Clin Pharm       Date:  2015-05-22

3.  Targeted cancer therapies, part 2 #277.

Authors:  Helen Gharwan; Hunter Groninger
Journal:  J Palliat Med       Date:  2014-02-14       Impact factor: 2.947

Review 4.  [Acute hypersensitivity reactions associated with monoclonal antibodies for targeted therapy].

Authors:  B Sachs; H F Merk
Journal:  Hautarzt       Date:  2018-04       Impact factor: 0.751

5.  Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance.

Authors:  Roberto A Maldonado; Robert A LaMothe; Joseph D Ferrari; Ai-Hong Zhang; Robert J Rossi; Pallavi N Kolte; Aaron P Griset; Conlin O'Neil; David H Altreuter; Erica Browning; Lloyd Johnston; Omid C Farokhzad; Robert Langer; David W Scott; Ulrich H von Andrian; Takashi Kei Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-29       Impact factor: 11.205

6.  A Neutralizing Antibody Assay Based on a Reporter of Antibody-Dependent Cell-Mediated Cytotoxicity.

Authors:  Yuling Wu; Jia J Li; Hyun Jun Kim; Xu Liu; Weiyi Liu; Ahmad Akhgar; Michael A Bowen; Susan Spitz; Xu-Rong Jiang; Lorin K Roskos; Wendy I White
Journal:  AAPS J       Date:  2015-07-24       Impact factor: 4.009

Review 7.  Desensitizations for chemotherapy and monoclonal antibodies: indications and outcomes.

Authors:  Karen S Hsu Blatman; Mariana C Castells
Journal:  Curr Allergy Asthma Rep       Date:  2014-08       Impact factor: 4.806

Review 8.  Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment.

Authors:  Joachim R Kalden; Hendrik Schulze-Koops
Journal:  Nat Rev Rheumatol       Date:  2017-11-21       Impact factor: 20.543

9.  Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses.

Authors:  Marisa K Joubert; Martha Hokom; Catherine Eakin; Lei Zhou; Meghana Deshpande; Matthew P Baker; Theresa J Goletz; Bruce A Kerwin; Naren Chirmule; Linda O Narhi; Vibha Jawa
Journal:  J Biol Chem       Date:  2012-05-14       Impact factor: 5.157

Review 10.  Drug allergy: causes and desensitization.

Authors:  Richard Warrington
Journal:  Hum Vaccin Immunother       Date:  2012-08-24       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.